Novartis 1Q Revenues: $12.7 billion (+10%) 1Q Earnings: $2.0 billion (+22%) Comments: Novartis Pharmaceuticals (Immunology, Hepatology & Dermatology) sales were $5.2 billion in the quarter. Cosentyx sales were $580 million, up 35% cc. Ilaris sales were $126 million, up 47% cc. In Cardio-Metabolic, Entresto sales were $200 million, up 126% cc. In Neuroscience, Gilenya sales were $821 million, up 8% cc. Respiratory sales were $433 million, up 7% cc driven by continued growth of Xolair with ...